Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Rating) was the recipient of a large decline in short interest in the month of December. As of December 30th, there was short interest totalling 111,700 shares, a decline of 5.7% from the December 15th total of 118,500 shares. Based on an average daily trading volume, of 1,640,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 1.4% of the shares of the company are short sold.
Dermata Therapeutics Stock Up 15.0 %
Shares of DRMA opened at $0.29 on Monday. Dermata Therapeutics has a 12-month low of $0.16 and a 12-month high of $2.45. The business has a 50-day simple moving average of $0.37 and a two-hundred day simple moving average of $0.56.
Dermata Therapeutics (NASDAQ:DRMA – Get Rating) last announced its quarterly earnings results on Thursday, November 10th. The company reported ($0.20) earnings per share (EPS) for the quarter. As a group, analysts expect that Dermata Therapeutics will post -0.82 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Institutional Trading of Dermata Therapeutics
A hedge fund recently bought a new stake in Dermata Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Rating) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 70,808 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned 0.70% of Dermata Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 1.63% of the stock is owned by hedge funds and other institutional investors.
About Dermata Therapeutics
Dermata Therapeutics, Inc, a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.
- Get a free copy of the StockNews.com research report on Dermata Therapeutics (DRMA)
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
- Chevron is Likely to Increase its Dividend Before Earnings
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.